Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

Université de Montréal

$105,000.00

Impact of Temsavir on HIV-1 Env conformation and soluble gp120-associated immune dysfunction

EF 2023-24

Résumé
Antiretroviral therapy (ART) is the only life-saving treatment for HIV-1 infection currently available. Although ART supresses viral replication in people living with HIV (PLWH), immune dysfunction and chronic inflammation persists. In most PLWH, aging-related diseases such as cardiovascular disease, osteoporosis, and neurocognitive diseases develop prematurely. It is still unclear how HIV infection maintains a profound effect on PLWH despite undetectable viral load. One of the hypotheses is the persistence of residual viral proteins, such as the gp120 subunit of the HIV-1 envelope (Env) glycoprotein. Besides its role during viral entry, gp120 is released from the Env complex as soluble gp120 (sgp120) and is detected in the plasma and tissues of PLWH. Importantly, it was demonstrated that sgp120 can exhibit a variety of immunoregulatory activities, potentially contributing to the persistent immune dysfunction and chronic inflammation that PLWH endure. Our research group is currently studying the role of a recently FDA-approved small-molecule gp120 inhibitor, Temsavir (TMR), which could potentially attenuate the immune dysfunction and chronic inflammation associated to sgp120 in PLWH. We have previously shown that TMR exerts drastic changes on Env conformation and functionality, while also reducing soluble gp120-mediated toxicity. Understanding the mechanism underlying the impact of TMR on Env could result in new therapeutic approaches for PLWH.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
496952
Name
Benlarbi Mehdi
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Impact of Temsavir on HIV-1 Env conformation and soluble gp120-associated immune dysfunction
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Elisa; Envelope Conformation; Envelope Glycoprotein; Flow Cytometry; Fostemsavir; Hiv-1; Humoral Responses; Molecular Mechanism; Pathogenesis; Primary Cells
Abstract
Antiretroviral therapy (ART) is the only life-saving treatment for HIV-1 infection currently available. Although ART supresses viral replication in people living with HIV (PLWH), immune dysfunction and chronic inflammation persists. In most PLWH, aging-related diseases such as cardiovascular disease, osteoporosis, and neurocognitive diseases develop prematurely. It is still unclear how HIV infection maintains a profound effect on PLWH despite undetectable viral load. One of the hypotheses is the persistence of residual viral proteins, such as the gp120 subunit of the HIV-1 envelope (Env) glycoprotein. Besides its role during viral entry, gp120 is released from the Env complex as soluble gp120 (sgp120) and is detected in the plasma and tissues of PLWH. Importantly, it was demonstrated that sgp120 can exhibit a variety of immunoregulatory activities, potentially contributing to the persistent immune dysfunction and chronic inflammation that PLWH endure. Our research group is currently studying the role of a recently FDA-approved small-molecule gp120 inhibitor, Temsavir (TMR), which could potentially attenuate the immune dysfunction and chronic inflammation associated to sgp120 in PLWH. We have previously shown that TMR exerts drastic changes on Env conformation and functionality, while also reducing soluble gp120-mediated toxicity. Understanding the mechanism underlying the impact of TMR on Env could result in new therapeutic approaches for PLWH.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Benlarbi, Mehdi
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~